USP Comments to FDA Public Meeting: “The Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access” Regarding Generic Medicines (2017)

USP Comments to FDA Public Meeting: “The Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access” Regarding Generic Medicines. Comments were submitted 7-18-2017.

2017-07-18-USP-Comments-on-Generics-(Advisory-Committee-Meeting).pdf (354.72 KB)

Public Policy